News Daily News Side Effects of Statins Might Be Overstated: CTT Collaboration Michael O'Riordan February 12, 2026
News Daily News Coverage and Use of Impella and Watchman: A Tale of Four Countries Michael O'Riordan March 04, 2025
News Daily News ‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials Michael O'Riordan February 20, 2025
News Daily News Little Pre- and Postmarket Testing for Most Recalled CV Devices Michael O'Riordan September 16, 2024
News Daily News FDA Approves Paradise Renal Denervation System: What Comes Next? Todd Neale November 08, 2023
News Daily News Medical Devices Cleared on Faulty Predicates More Likely to be Recalled Michael O'Riordan January 17, 2023
News Daily News Higher Annual TAVI Volumes Linked to Greater Use of Embolic Protection L.A. McKeown August 23, 2022
News Features Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD? Michael O'Riordan August 15, 2022
News Conference News TVT 2022 Non-COAPT-Like Patients Fare Well With MitraClip, EXPAND Suggests Michael O'Riordan June 09, 2022
News Daily News FDA Grants Expanded Indication to CardioMEMS PA Pressure Monitor Shelley Wood February 22, 2022
News Features Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path Michael O'Riordan January 17, 2022
News Daily News British Medical Groups Express Concern About Inclisiran Rollout Michael O'Riordan December 14, 2021
News Daily News Papers Probe Temporal Link Between COVID-19 Vaccines and Myocarditis Michael O'Riordan June 17, 2021
News Daily News Add-on CMS Payment Sweetens Shockwave Choice, but Cost Still Rankles Michael O'Riordan May 12, 2021
News Features Roughly 80% of ESC Guideline Writers Have Financial COIs Michael O'Riordan April 01, 2021
News Daily News Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval Michael O'Riordan March 03, 2021
News Features Funding the Future: How Industry Support for CV Trials Could Evolve Michael O'Riordan December 17, 2020